Does age influence the behaviour of localized prostate cancer?

BJU International

Volumn 87, Issue 7, 2001, Pages 629-637

  Parker, C C ^a   Gospodarowicz, M ^a   Warde, P ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Age; Localized; Meta analysis; Outcome; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; BLOOD LEVEL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA;

AGE FACTORS; AGED; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0035732988     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2001.02141.x     Document Type: Article

References (65)

1. Competing risk analysis of men aged 55-74 years at diagnosis managed conservatively for clinically localised prostate cancer
2. Age-related prostate cancer metastases
3. Age as a prognostic factor for disease recurrence after radical prostatectomy
4. Age-race interaction in prostatic adenocarcinoma treated with external beam irradiation
5. Prostate adenocarcinoma in men younger than 50 years. A retrospective review of 151 patients
6. Carcinoma of prostate in men less than fifty years old. Data from American College of Surgeons' national survey
7. Prostatic adenocarcinoma occurring in men under 50 years of age
8. Clinical course of early onset prostate cancer with special reference to family history as a prognostic factor
9. A comparison by age of death rates due to prostate cancer alone
10. Natural history and prognosis of prostate carcinoma in adolescents and men under 35 years of age
11. Clinical adenocarcinoma of the prostate in patients under 50 years of age
12. Cancer of the prostate in men less than 50 years old: An analysis of 51 cases
13. Adenocarcinoma of the prostate in men less than 56 years old: A study of 65 cases
14. A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995
15. Patient age as a prognostic factor in prostate cancer
16. Mortality in prostate cancer
17. Cancer of the prostate. Do younger men have a poorer survival rate?
18. Pathological stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate
19. Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease
20. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy
21. Radical prostatectomy for clinically localised prostate cancer: Long-term results of 1,143 patients from a single institution
22. Radical prostatectomy and prognostic factors
23. Results of conservative management of clinically localised prostate cancer
24. Carcinoma of the prostate: Results of radical radiotherapy (1970-85)
25. Survival after radical prostatectomy
26. Factors influencing outcome of definitive radiotherapy for localised carcinoma of the prostate
27. Long-term survival after radiotherapy alone: Radiation therapy oncology group prostate cancer trials
28. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy
29. Patterns of care outcome studies: Results of the national practice in adenocarcinoma of the prostate
30. The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement
31. Prognostic significance of p16 and CDK4 proteins in localised prostate carcinoma
32. A model to predict biochemical (PSA) control after radical radiotherapy with initial androgen suppression for clinically localised prostate cancer
33. Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer
34. Prostate specific antigen nadir following external beam radiation therapy for clinically localised prostate cancer: The relationship between nadir level and disease-free survival
35. Localised prostate cancer in elderly patients. Outcome after radiation therapy compared to matched younger patients
36. Long-term impact of conservative management on localised prostate cancer. A twenty-year experience in Japan
37. Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients
38. Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome
39. Radiotherapy for localised prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen
40. Deferred treatment of localised prostate cancer in the elderly: The impact of the age and stage at the time of diagnosis on the treatment decision
41. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results
42. Race as an independent predictor of outcome after treatment for localised prostate cancer
43. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer
44. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma
45. SEER cancer statistic review 1973-91
46. Removal of the financial barrier to health care: Does it impact on prostate cancer at presentation and survival? A comparative study between black and white men in a Veterans affairs system
47. Should African-American men be tested for prostate carcinoma at an earlier age than white men?
48. Dilemmas in treating early prostate cancer: The evidence and a questionnaire survey of consultant urologists in the UK
49. Primary treatment choices for men with clinically localised prostate carcinoma detected by screening
50. The National Cancer Data Base report on race, age, and region variations in prostate cancer treatment
51. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade
52. Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: A phase I assessment
53. RTOG Protocol 92-02: A phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate
54. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group
55. Beneficial effect of combination hormonal therapy administered prior to and during external beam radiation therapy in localised prostate cancer
56. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localised prostate cancer
57. Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed army medical center experience, 1988-95
58. Results of radical prostatectomy in men with clinically localised prostate cancer
59. Prognostic factors for clinically localised prostate carcinoma: Analysis of 938 patients irradiated in the prostate specific antigen era
60. Results of 3D conformal radiotherapy in the treatment of localised prostate cancer
61. A multiple prognostic index predictive of disease outcome after irradiation for clinically localised prostate carcinoma
62. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer
63. Young men with prostate cancer treated by simultaneous radiotherapy
64. Prostate cancer is highly predictable: A prognostic equation based on all morphological variables in radical prostatectomy specimens
65. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma